


PTO-1449 REPRODUCTION

INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION

(Use several sheets if necessary)



#15

ATTORNEY DOCKET NO.  
00537-161002APPLICATION NO.  
09/423,684APPLICANT  
Michael Anthony Cawthorne et al.FILING DATE  
March 20, 2000GROUP  
1653APR 29 2003  
JH CENTER 1600/2800

RECEIVED

## U.S. PATENT DOCUMENTS

EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
AM	BA	5,506,339	04/09/96	Coy et al.	530	311	
	BB	4,904,642	02/27/90	Coy et al.	514	11	
	BC	4,871,717	10/03/89	Coy et al.	514	11	
	BD	4,853,371	08/01/89	Coy et al.	514	12	
	BE	4,728,638	03/01/88	Bauer et al.	514	11	
	BF	4,725,577	02/16/88	Schally et al.	514	11	
	BG	4,684,620	08/04/87	Hruby et al.	514	11	
	BH	4,650,787	03/17/87	Schally et al.	514	11	
	BI	4,603,120	07/29/86	Kamber	514	11	
	BJ	4,585,755	04/29/86	Morgan et al.	514	11	
	BK	4,522,813	06/11/85	Nutt	514	11	
	BL	4,486,415	12/04/84	Freidinger	514	11	
	BM	4,485,101	11/27/84	Coy et al.	514	11	
	BN	4,435,385	03/06/84	Bauer et al.	514	11	
	BO	4,395,403	07/26/83	Bauer et al.	514	12	
	BP	4,369,179	01/18/83	Rink et al.	514	11	
	BQ	4,360,516	11/23/82	Freidinger et al.	514	11	
	BR	4,358,439	11/09/82	Sieber et al.	514	11	
	BS	4,328,214	05/04/82	Rink et al.	514	11	
	BT	4,316,890	02/23/82	Kamber et al.	514	11	
	BU	4,310,518	01/12/82	Freidinger et al.	424	177	
	BV	4,291,022	09/22/81	Sandrin et al.	424	177	
EXAMINER <i>Hope Robinson</i>				DATE CONSIDERED 2/18/04			



PTO-1449 REPRODUCE

**INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION**

(Use several sheets if necessary)

ATTORNEY DOCKET NO.  
00537-161002

APPLICATION NO.  
09/423,684

APPLICANT  
Michael Anthony Cawthorne et al.

FILING DATE  
March 20, 2000

GROUP  
1653

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
<input checked="" type="checkbox"/>	BW	EP 0 505 680	09/30/92	European	—	—	
<input checked="" type="checkbox"/>	BX	EP 0 389 180	09/26/90	European	—	—	
<input checked="" type="checkbox"/>	BY	EP 0 363 589	04/18/90	European	—	—	
<input checked="" type="checkbox"/>	BZ	EP 0 329 295	08/23/89	European	—	—	
<input checked="" type="checkbox"/>	BAA	EP 0 203 031	11/26/86	European	—	—	
<input checked="" type="checkbox"/>	BBB	FR 2 522 655	09/09/83	France	—	—	
<input checked="" type="checkbox"/>	BCC	GB 2 095 261	09/29/82	United Kingdom	—	—	
<input checked="" type="checkbox"/>	BDD	WO 97/01579	01/16/97	PCT	—	—	
<input checked="" type="checkbox"/>	BEE	WO 91/18016	11/28/91	PCT	—	—	

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

<input checked="" type="checkbox"/>	BFF	CARRETTA, R. et al., "Reduction of Blood Pressure in Obese Hyperinsulinaemic Hypertensive Patients During Somatostatin Infusion", Journal of Hypertension, 7(6):S196-S197 (1989).
<input checked="" type="checkbox"/>	BGG	CLARK, J. A. et al., "Multiple Regions of Ligand Discrimination Revealed by Analysis of Chimeric Parathyroid Hormone 2 (PTH2) and PTH/PTH-Related Peptide (PTHrP) Receptors", Molecular Endocrinology, 12(2):193-206 (1998).
<input checked="" type="checkbox"/>	BHH	HUANG, H.-J. et al., "Hyperamylinemia, Hyperinsulinemia, and Insulin Resistance in Genetically Obese LA/N-cp Rats", Supplement to Hypertension, 19(1):I-101-I109 (1992).
<input checked="" type="checkbox"/>	BIT	LUNETTA, M. et al., "Long-Term Octreotide Treatment Reduced Hyperinsulinemia, Excess Body Weight and Skin Lesions in Severe Obesity With Acanthosis Nigricans", J. Endocrinol. Invest., 19:699-703 (1996).
<input checked="" type="checkbox"/>	BJJ	VAN BINST, G. et al., "Backbone Modifications in Somatostatin Analogues: Relation Between Conformation and Activity", Peptide Research, 5(1):8-13 (1992).
<input checked="" type="checkbox"/>	BKK	ZAMBONI, M. et al., "Obesity and Regional Body-Fat Distribution in Men: Separate and Joint Relationships to Glucose Tolerance and Plasma Lipoproteins", Am J Clin. Nutrition, 60:682-687 (1994).

EXAMINER

*Hope Robinson*

DATE CONSIDERED

*2/18/04*

09/423684

Sheet 1 of 1

Substitute Form PTO-1449  
(Modified)

U.S. Department of Commerce  
Patent and Trademark Office

Attorney's Docket No.  
00537-161002

Application No.  
420 Rec'd PCT/PTO 10 NOV 1999

**Information Disclosure Statement  
by Applicant**  
(Use several sheets if necessary)

(37 CFR §1.98(b))

Applicant  
Michael Anthony Cawthorne et al.

Filing Date

Group Art Unit

U.S. Patent Documents							
Examiner Initial	Desig. ID	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date If Appropriate
AR	AA	5708135	13-01-1998		530	311	
	AB	5763200	09-06-1998		435	7.21	
	AC	5583104	10-12-1996		514	11	
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
AR	AL	WO9711962	03-04-1997	PCT			Yes	No
	AM	WO9810786	19-03-1998	PCT				
	AN	WO9809991	12-03-1998	PCT				
	AO	WO9635950	14-11-1996	PCT				
	AP	EP0657174	14-06-1995	EP				

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	AQ	
	AR	
	AS	
	AT	

Examiner Signature  
*Hope Robinson*

Date Considered  
2/19/04

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Disclosure Form (PTO-1449)